October 30, 2017
Novartis expands its oncology arm with AAA
Novartis said on Monday that it wants to buy Advanced Accelerator Applications (AAA), a radiopharmaceutical company that owns and sells…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: oncology
September 20, 2017
EC approves Novartis’s cancer drug for 2 indications
The European Commission has approved Novartis’s Rydapt for two indications in rare cancers, in combination with standard daunorubicin and cytarabine…
September 11, 2017
Targovax with three oncology posters at ESMO in Spain
Targovax ASA, a clinical stage company focused on immuno-oncology therapies against solid tumors, on Monday revealed that three posters were…
July 27, 2017
Merck, AstraZeneca in a $8.5 billion oncology deal
AstraZeneca and Merck on Thursday said that they have made a deal to co-develop and co-commercialise AstraZeneca’s oncology product Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.
June 28, 2017
Vivace in $40M financing raised in two venture rounds, investors from U.S. and China
Vivace Therapeutics, an oncology-focused portfolio-based drug discovery and development company is coming out of stealth with $40 million raised in Series A and B financings.
April 28, 2017
Novartis’s oncology department gets FDA’s OK for two indications
Novartises Rydapt has been approved by the FDA for the treatment of acute myeloid leukemia, and for treating adults with advanced systemic mastocytosis.
April 5, 2017
Heptares trigers milestone payment from AstraZeneca
Sosei Group Corporation’s subsidiary Heptares Therapeutics got milestone payment from AstraZeneca for working together on an immuno-oncology project.
March 15, 2017
AstraZeneca’s olaparib tablets as a maintenance therapy for patients with relapsed ovarian cancer
AstraZeneca’s trial treating relapsed ovarian cancer patients with olaparib met its primary endpoint, the company said Tuesday.
February 21, 2017
BMS in $2 Billion accelerated share repurchase program, names 3 new directors
Bristol-Myers Squibb has entered into an ASR program with each of Morgan Stanley & Co. LLC and Goldman, Sachs & Co. to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock, and it has named three new directors.
February 21, 2017
$100 million for Global HOPE to treat children with cancer and blood disorders, training for 4,800 healthcare pros in Africa
Botswana will be a centert for southern and east Africa for hematology-oncology treatment, as it will get a new $100…